

## Accepted Manuscript

Ebola virus vaccines: Where do we stand?

Vincent Pavot

PII: S1521-6616(16)30536-8  
DOI: doi:[10.1016/j.clim.2016.10.016](https://doi.org/10.1016/j.clim.2016.10.016)  
Reference: YCLIM 7757

To appear in: *Clinical Immunology*

Received date: 24 October 2016  
Accepted date: 26 October 2016

Please cite this article as: Vincent Pavot, Ebola virus vaccines: Where do we stand?, *Clinical Immunology* (2016), doi:[10.1016/j.clim.2016.10.016](https://doi.org/10.1016/j.clim.2016.10.016)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## **Ebola virus vaccines: where do we stand?**

**Vincent Pavot**

**The Jenner Institute, University of Oxford, Oxford, UK.**

### *Abstract*

The recent outbreak of Ebola virus disease in West Africa has led to more than 11,000 deaths, with a peak in mortality from August through December of 2014. A meeting convened by the World Health Organization (WHO) in September, 2014, concluded that an urgent unmet need exists for efficacy and safety testing of the Ebola virus vaccine candidates and that clinical trials should be expedited. These vaccines could be used both in an outbreak setting and to provide long-term protection in populations at risk of sporadic outbreaks.

A number of vaccines have been evaluated in phase 1 trials, but the two most advanced first-generation Ebola vaccine candidates are the live replicating vesicular stomatitis virus (rVSV) and the replication-defective chimpanzee adenovirus 3 (ChAd3).

This review focuses on these two vaccines in clinical development and discusses the future opportunities and challenges faced in the licensure and deployment of Ebola virus vaccines.

**Keywords:** Clinical trials; Ebola virus; Immunology; Vaccines; Viral vectors.

ACCE

Download English Version:

<https://daneshyari.com/en/article/5654958>

Download Persian Version:

<https://daneshyari.com/article/5654958>

[Daneshyari.com](https://daneshyari.com)